| Literature DB >> 36091379 |
Xinghao Wang1, Chen Xu2, Marcin Grzegorzek3, Hongzan Sun1.
Abstract
Purpose: We aim to develop and validate PET/ CT image-based radiomics to determine the Ki-67 status of high-grade serous ovarian cancer (HGSOC), in which we use the metabolic subregion evolution to improve the prediction ability of the model. At the same time, the stratified effect of the radiomics model on the progression-free survival rate of ovarian cancer patients was illustrated. Materials and methods: We retrospectively reviewed 161 patients with HGSOC from April 2013 to January 2019. 18F-FDG PET/ CT images before treatment, pathological reports, and follow-up data were analyzed. A randomized grouping method was used to divide ovarian cancer patients into a training group and validation group. PET/ CT images were fused to extract radiomics features of the whole tumor region and radiomics features based on the Habitat method. The feature is dimensionality reduced, and meaningful features are screened to form a signature for predicting the Ki-67 status of ovarian cancer. Meanwhile, survival analysis was conducted to explore the hierarchical guidance significance of radiomics in the prognosis of patients with ovarian cancer.Entities:
Keywords: Habitat; Ki-67; PET/CT; high-grade serous ovarian cancer; progression-free survival; radiomics
Year: 2022 PMID: 36091379 PMCID: PMC9452776 DOI: 10.3389/fphys.2022.948767
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.755
FIGURE 1Schematic diagram of study design.
FIGURE 2Schematic diagram of Habitat method. (a) The blue area represents the whole tumor area; (b) Based on the whole tumor area, we have implemented the subarea partition by habitat algorithm.
Clinical characteristics of HGSOC patients in training and test groups.
| Characteristic | Training group (n = 112) | Test group (n = 49) |
|
|---|---|---|---|
| Age, mean ± SD, year | 53.22±9.31 | 53.43±10.52 |
|
| NACT |
| ||
| Yes | 43 | 13 | |
| No | 69 | 36 | |
| LNM | |||
| Yes | 59 | 29 |
|
| No | 53 | 20 | |
| FIGO stage |
| ||
| Stage III | 72 | 33 | |
| Stage IV | 40 | 16 | |
| Ascites |
| ||
| <200 ml | 61 | 24 | |
| 200ml–1000 ml | 37 | 19 | |
| >1000 ml | 14 | 6 | |
Description of two models.
| Model | Standardization method | Feature selection method | Characteristic quantity | Model classifier |
|---|---|---|---|---|
|
| Z-score | Recursive feature elimination | 20 | Auto-encoder |
|
| Z-score | Kruskal–Wallis | 8 | Logistic regression |
FIGURE 3The ROC and calibration curve of R and Rhabitat. (a) The performance of training set and validation set on model R (based on whole tumor); (b) The performance of training set and validation set on model Rhabitat (based on different metabolic sub-regions). (c) Demonstrate the calibration effect of the R model; (d) Demonstrate the calibration effect of the Rhabitat model.
FIGURE 4Decision curve analysis for R and Rhabitat.
FIGURE 5The survival curves of Rhabitat.